TABLE 1.
Antimicrobial susceptibility profiles
| Antibiotic | MIC (mg/liter)/antimicrobial susceptibilitya
|
||
|---|---|---|---|
| C. braakii CRE3 | Electroporant CRE3-KPC-DH5α | E. coli DH5α | |
| Ampicillin | ≥32/R | ≥32/R | ≤2/R |
| Piperacillin | ≥128/R | ≥128/R | ≤4/S |
| Cefuroxime | ≥64/R | ≥64/R | 4/S |
| Ceftriaxone | ≥64/R | ≥64/R | ≤1/S |
| Ceftazidime | ≥64/R | 4/S | ≤1/S |
| Cefepime | ≥64/R | ≤1/S | ≤1/S |
| Aztreonam | ≥64/R | ≥64/R | ≤1/S |
| Imipenem | ≥16/R | ≥16/R | ≤1/S |
| Meropenem | ≥16/R | ≥16/R | ≤0.25/S |
| Amikacin | 32/I | ≤2/S | ≤2/S |
| Gentamicin | ≥16/R | ≥16/R | ≤1/S |
| Tobramycin | ≥16/R | 2/S | ≤2/S |
| Ciprofloxacin | ≥4/R | ≤0.25/S | ≤0.25/S |
| Levofloxacin | 4/I | ≤0.25/S | ≤0.25/S |
| Nitrofurantoin | 128/R | ≤16/S | ≤16/S |
a
The interpretation is derived from the Clinical and Laboratory Standards Institute guidelines (CLSI, 2018) (S, sensitive; R, resistant; I, intermediately resistant).